Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study

The rapid emergence of antimicrobial-resistant pathogens and the declining efficacy of conventional antibiotics have intensified the search for alternative therapeutic strategies. PdTPPS 4 (palladium(II) meso-tetra(4-sulphonatophenyl)porphyrin) is a novel water-soluble photosensitiser with promising photodynamic and antibacterial potential. In the current study, the dermatotoxicological profile of this compound was evaluated by using a number of mechanism-informed, validated non-animal methods. The in vitro assays undertaken in the current study were modified to achieve optimised conditions, but were based on the following Organisation for Economic Co-operation and Development (OECD) Test Guidelines: TG 439 ( in vitro skin irritation testing, with reconstructed human epidermis); and, for the evaluation of skin sensitisation potential, TG 442D (specifically, the ARE-Nrf2 luciferase test method (LuSens assay)) and TG 442C (the Direct Peptide Reactivity Assay (DPRA)). An immunoassay-based assessment of early inflammatory biomarkers (IL-1α, IL-18) was also performed, in order to detect potential sub-irritant responses. PdTPPS 4 showed no indication of skin irritation, inflammatory activation or sensitisation potential under the test conditions. These findings support the favourable dermal compatibility of PdTPPS 4 under non-irradiated (dark) conditions, and indicate low intrinsic dermatotoxicity in the tests performed. This study provides initial toxicological evidence supporting further investigation of PdTPPS 4 as a promising candidate photosensitiser, for use in future antimicrobial photodynamic therapy applications. These results not only demonstrate the dermatological safety of PdTPPS 4 , but also introduce a new methodological framework for the preclinical safety screening of photosensitisers by using exclusively non-animal OECD-guided assays. The current non-animal and mechanism-informed assessment of dermal toxicity contributes to both the ethical and translational advancement in the development of photodynamic therapeutic agents, supporting regulatory and clinical decision-making with regard to these compounds.

Authors

Institutions

Publication Details

Journal
Alternatives to Laboratory Animals
Published
2026-11-21
DOI
https://doi.org/10.1177/02611929261506474
Primary Topic
Photodynamic Therapy Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study

Hana Bendová, Hanna Dilenko, Markéta Kolaříková, Robert Bajgar et al.
Alternatives to Laboratory Animals
Photodynamic Therapy Research Studies
article

Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study

Hana Bendová, Hanna Dilenko, Markéta Kolaříková, Robert Bajgar, Kristína Kejlová, Marián Rucki, Hana Kolářová, Katerina Barton Tomankova, Lada Svobodová, Lucie Válková
article en

Abstract

The rapid emergence of antimicrobial-resistant pathogens and the declining efficacy of conventional antibiotics have intensified the search for alternative therapeutic strategies. PdTPPS 4 (palladium(II) meso-tetra(4-sulphonatophenyl)porphyrin) is a novel water-soluble photosensitiser with promising photodynamic and antibacterial potential. In the current study, the dermatotoxicological profile of this compound was evaluated by using a number of mechanism-informed, validated non-animal methods. The in vitro assays undertaken in the current study were modified to achieve optimised conditions, but were based on the following Organisation for Economic Co-operation and Development (OECD) Test Guidelines: TG 439 ( in vitro skin irritation testing, with reconstructed human epidermis); and, for the evaluation of skin sensitisation potential, TG 442D (specifically, the ARE-Nrf2 luciferase test method (LuSens assay)) and TG 442C (the Direct Peptide Reactivity Assay (DPRA)). An immunoassay-based assessment of early inflammatory biomarkers (IL-1α, IL-18) was also performed, in order to detect potential sub-irritant responses. PdTPPS 4 showed no indication of skin irritation, inflammatory activation or sensitisation potential under the test conditions. These findings support the favourable dermal compatibility of PdTPPS 4 under non-irradiated (dark) conditions, and indicate low intrinsic dermatotoxicity in the tests performed. This study provides initial toxicological evidence supporting further investigation of PdTPPS 4 as a promising candidate photosensitiser, for use in future antimicrobial photodynamic therapy applications. These results not only demonstrate the dermatological safety of PdTPPS 4 , but also introduce a new methodological framework for the preclinical safety screening of photosensitisers by using exclusively non-animal OECD-guided assays. The current non-animal and mechanism-informed assessment of dermal toxicity contributes to both the ethical and translational advancement in the development of photodynamic therapeutic agents, supporting regulatory and clinical decision-making with regard to these compounds.

Alternatives to Laboratory Animals
Technical University of Liberec (CZ), Palacký University Olomouc (CZ)
Photodynamic Therapy Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon